We are live on ! Find out more
IMUC

ImmunoCellular Therapeutics, Ltd.
IMUC

Delisted

IMUC was delisted on the 16th of October, 2018.

18 hedge funds and large institutions have $348K invested in ImmunoCellular Therapeutics, Ltd. in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

57% more capital invested

Capital invested by funds: $221K → $348K (+$127K)

13% more funds holding

Funds holding: 1618 (+2)

Holders
18
Holders Change
+2
Holders Change %
+12.5%
% of All Funds
0.45%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
3
Reduced
1
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$254K +$267K +548,800 +417%
Vanguard Group
2
Vanguard Group
Pennsylvania
$23K -$300 -617 -1%
WS
3
Wedbush Securities
California
$23K +$11.7K +24,030 +64%
UBS Group
4
UBS Group
Switzerland
$16K +$21.4K +43,963 +35,170%
VF
5
Virtu Financial
New York
$12K +$15.3K +31,387 New
Bank of New York Mellon
6
Bank of New York Mellon
New York
$10K +$12.2K +25,029 New
TSS
7
Two Sigma Securities
New York
$5K +$7.1K +14,600 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$4K
NFG
9
Next Financial Group
Texas
$1K +$1.46K +3,000 New
RE
10
RBC Europe
United Kingdom
$1 +$1 +2 New
Bank of America
11
Bank of America
North Carolina
+$8 +16 New